Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Quilici

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Journal of the American College of Cardiology|September 19, 2009
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized studyThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 9, 2009
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?Thomas Cuisset, Guillaume Cayla, Corinne Frere, et al.
Thrombosis Research|March 6, 2007
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndromeThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Thrombosis and Haemostasis|February 1, 2007
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromesThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Journal of the American College of Cardiology|October 3, 2006
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stentingThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
International Journal of Cardiology|November 16, 2013
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparisonPierre Deharo, Clemence Bassez, Guillaume Bonnet, et al.
Thrombosis Research|May 24, 2008
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non responseThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
International Journal of Cardiology|May 7, 2013
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndromeThomas Cuisset, Guillaume Cayla, Jacques Quilici, et al.
Thrombosis Research|September 11, 2010
Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary SyndromeThomas Cuisset, Corinne Frere, Pierre Julien Moro, et al.
Thrombosis Research|September 10, 2010
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation)Raphaël Poyet, Thomas Cuisset, Corinne Frere, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Journal of the American College of Cardiology|September 19, 2009
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized studyThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 9, 2009
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?Thomas Cuisset, Guillaume Cayla, Corinne Frere, et al.
Thrombosis Research|March 6, 2007
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndromeThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Thrombosis and Haemostasis|February 1, 2007
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromesThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
Journal of the American College of Cardiology|October 3, 2006
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stentingThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
International Journal of Cardiology|November 16, 2013
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparisonPierre Deharo, Clemence Bassez, Guillaume Bonnet, et al.
Thrombosis Research|May 24, 2008
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non responseThomas Cuisset, Corinne Frere, Jacques Quilici, et al.
International Journal of Cardiology|May 7, 2013
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndromeThomas Cuisset, Guillaume Cayla, Jacques Quilici, et al.
Thrombosis Research|September 11, 2010
Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary SyndromeThomas Cuisset, Corinne Frere, Pierre Julien Moro, et al.
Thrombosis Research|September 10, 2010
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation)Raphaël Poyet, Thomas Cuisset, Corinne Frere, et al.
Pageof 8